Dianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year Low - What's Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report)'s stock price hit a new 52-week low during trading on Tuesday . The company traded as low as $17.40 and last traded at $17.47, with a volume of 12685 shares trading hands. The stock had previously closed at $18.14.

Analysts Set New Price Targets

DNTH has been the subject of a number of analyst reports. Raymond James raised Dianthus Therapeutics to a "moderate buy" rating in a report on Thursday, December 12th. Wedbush restated an "outperform" rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They set a "buy" rating on the stock. Finally, Guggenheim reaffirmed a "buy" rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $54.33.

Dianthus Therapeutics Price Performance

The stock has a market cap of $517.86 million, a price-to-earnings ratio of -6.45 and a beta of 1.62. The firm's 50-day moving average is $21.48 and its 200 day moving average is $23.92.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping analysts' consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. On average, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of DNTH. Wellington Management Group LLP raised its holdings in Dianthus Therapeutics by 12.2% in the fourth quarter. Wellington Management Group LLP now owns 60,337 shares of the company's stock valued at $1,315,000 after buying an additional 6,552 shares during the period. Woodline Partners LP raised its stake in shares of Dianthus Therapeutics by 20.0% in the 4th quarter. Woodline Partners LP now owns 300,504 shares of the company's stock valued at $6,551,000 after acquiring an additional 50,000 shares during the period. Vestal Point Capital LP raised its stake in shares of Dianthus Therapeutics by 172.2% in the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock valued at $23,435,000 after acquiring an additional 680,000 shares during the period. Octagon Capital Advisors LP boosted its position in Dianthus Therapeutics by 20.8% during the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock worth $46,002,000 after purchasing an additional 363,500 shares during the period. Finally, Millennium Management LLC increased its holdings in Dianthus Therapeutics by 160.2% in the 4th quarter. Millennium Management LLC now owns 90,436 shares of the company's stock valued at $1,972,000 after purchasing an additional 55,682 shares in the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.